RheumMadness 2025: The Innovation Invitational: Rheum2Learn's Entry #842513

Rheum2Learn's Entry #842513

Entry ID: 842513

Participant Name: Rheum2Learn

Points: 0 View Scoring Rules

Rank: 0

Tie Breaker:

2nd Tie Breaker:

Permalink: Embed:

Printer Friendly Version

Entry Picks

The bracket below shows this entry's picks compared to the current results.
The correct picks are shown in green and the incorrect picks are shown in red.

CD40L in Sjogren's

ABA in Pre-RA

Anifrolumab extension

CD40L in Sjogren's

TYK2 in SLE

HCQ Screen Cost

SGCAPS

STRAP Trial

Obinutuzumab in LN

BiTEs

TYK2 in SLE

HCQ Screen Cost

Obinutuzumab in LN

BiTEs

Obinutuzumab in LN

BiTEs

Comments

The competition was tough. I feel BiTes have the potential to have the biggest impact. CAR-T is impressive but too risky and expensive to have a wide impact. TYK2 but not just for SLE was a close second. And CD40L would be welcome to treat a disease with very few options.

Posted by Rheum2Learn This is my entry. 3/20/2025 2:38:57 PM

RheumMadness 2025: The Innovation Invitational

Rheum2Learn's Entry #842513

Entry Picks

Comments

Leave a Comment

Contact David Leverenz